1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis award supports larger, more complex translational studies than Funding Level 1, including advanced preclinical and/or clinical research aimed at moving candidate therapies into IND-enabling studies. It seeks to accelerate promising ideas toward clinical application.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Unrestricted, open to any type of entity. Preliminary data is required. Clinical trials, including pilot clinical trials and clinical trial readiness studies, are allowed. Confirm the full requirements in the official notice before applying.
The current listing shows up to $1,750,000 (Single PI) or $1,900,000 (Partnering PI Option) over 4 years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was September 4, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award - Funding Level 2 is funded by Department of Defense, Defense Health Agency Contracting Activity (DHACA). Verify program details on the funder's official page before applying.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Past winners and funding trends for this program
Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award - Funding Level 1 is sponsored by Department of Defense, Defense Health Agency Contracting Activity (DHACA). This award supports translational studies beyond basic research with the potential for near-term impact in clinical research or application. It funds small-scale preclinical and/or clinical research to support clinical trial readiness.
DOD Duchenne Muscular Dystrophy, Clinical/Translational Research Award is sponsored by Department of Defense, Defense Health Agency Contracting Activity (DHACA). This award supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. Research must address at least one of the FY26 CTRA Focus Areas.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:• The Established Investigator category is for independent investigators at all academic levels, or equivalent• The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.• The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required for all applications. Clinical trials or clinical trial aims are not allowed. Funding Opportunity Number: HT942526DMDRPIDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2.5M total program funding.
Clinical Translational Research Award (FY26 DMDRP) is sponsored by Congressionally Directed Medical Research Programs (CDMRP) - Duchenne Muscular Dystrophy Research Program (DMDRP). Supports translational studies beyond basic research with potential for near-term clinical impact. This includes small-scale preclinical and/or clinical research to support clinical trial readiness, and large, complex preclinical and/or clinical research (e.
CDMRP's FY26 portfolio funds 34 programs, and October 2026 is dense with full-application deadlines: PRCRP October 5, PCRP October 7, MRP October 14. Every one of them is gated behind a pre-application that closed months earlier. Here is what that two-step structure actually costs applicants, and how to be inside the gate for FY27.
Read articleThe Department's FY26 SBIR/STTR Release 3 opened June 24 with roughly 37 topics across DARPA, the Navy, the Air Force, and the defense components, all closing July 22. The compressed four-week window is unforgiving, but the bigger mistake founders make is treating every component the same. Here is how to read the release, the eligibility rules that disqualify good companies, and why the component you target matters more than the topic you pick.
Read articleDoW's 2026 SBIR Broad Agency Announcement now operates on a monthly pre-release / quarterly close cadence. The 42 topics closing June 24 are the first test of whether the new rhythm produces the steady-state deal flow defense innovators have been asking for since 2022.
Read article